Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp Completes First-In-Human Clinical Trial of IntellaTip MiFi XP Ablation Catheter For Patients With Type1 Atrial Flutter


Monday, 6 May 2013 08:00am EDT 

Boston Scientific Corp announced that it has completed a first-in-human clinical trial utilizing the IntellaTip MiFi XP Ablation Catheter for the treatment of type1 atrial flutter, an arrhythmia originating in the right atrium of the heart that affects nearly one million people in the United States. This single center feasibility trial enrolled 10 patients and was led by Prash Sanders, MBBS, PhD, FHRS, director of the Centre for Heart Rhythm Disorders at the University of Adelaide and the Royal Adelaide Hospital. Patients with type 1 atrial flutter may exhibit symptoms that include palpitations, shortness of breath, fatigue, lightheadedness and fainting. Catheter ablation, a procedure in which localized electrical energy is delivered into the heart tissue aimed at restoring the continuous normal rhythm, has become a first-line treatment approach for patients with recurrent type1 atrial flutter and demonstrates more successful short- and long-term outcomes compared to anti-arrhythmic drug therapy. The IntellaTip MiFi XP Catheter is the first addition to the IntellaTip family of ablation catheters Boston Scientific expects to unveil over the coming years. This new line of ablation catheters is designed to provide physicians with high resolution, precise, multidimensional information through sophisticated micro-sensors at the tip of the catheter. 

Company Quote

13.15
-0.11 -0.83%
19 Dec 2014